315 related articles for article (PubMed ID: 24317012)
1. The role of reduced intracellular concentrations of active drugs in the lack of response to anticancer chemotherapy.
Marin JJ; Monte MJ; Blazquez AG; Macias RI; Serrano MA; Briz O
Acta Pharmacol Sin; 2014 Jan; 35(1):1-10. PubMed ID: 24317012
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of Resistance to Chemotherapy in Gastric Cancer.
Marin JJ; Al-Abdulla R; Lozano E; Briz O; Bujanda L; Banales JM; Macias RI
Anticancer Agents Med Chem; 2016; 16(3):318-34. PubMed ID: 26234359
[TBL] [Abstract][Full Text] [Related]
3. Molecular Bases of Mechanisms Accounting for Drug Resistance in Gastric Adenocarcinoma.
Marin JJG; Perez-Silva L; Macias RIR; Asensio M; Peleteiro-Vigil A; Sanchez-Martin A; Cives-Losada C; Sanchon-Sanchez P; Sanchez De Blas B; Herraez E; Briz O; Lozano E
Cancers (Basel); 2020 Jul; 12(8):. PubMed ID: 32751679
[TBL] [Abstract][Full Text] [Related]
4. Tumor intracellular redox status and drug resistance--serendipity or a causal relationship?
Pervaiz S; Clement MV
Curr Pharm Des; 2004; 10(16):1969-77. PubMed ID: 15180532
[TBL] [Abstract][Full Text] [Related]
5. Molecular Bases of Chemoresistance in Cholangiocarcinoma.
Marin JJG; Lozano E; Briz O; Al-Abdulla R; Serrano MA; Macias RIR
Curr Drug Targets; 2017; 18(8):889-900. PubMed ID: 25706108
[TBL] [Abstract][Full Text] [Related]
6. Molecular mechanisms for tumour resistance to chemotherapy.
Pan ST; Li ZL; He ZX; Qiu JX; Zhou SF
Clin Exp Pharmacol Physiol; 2016 Aug; 43(8):723-37. PubMed ID: 27097837
[TBL] [Abstract][Full Text] [Related]
7. Genetic variants in genes involved in mechanisms of chemoresistance to anticancer drugs.
Marin JJ; Briz O; Monte MJ; Blazquez AG; Macias RI
Curr Cancer Drug Targets; 2012 May; 12(4):402-38. PubMed ID: 22229248
[TBL] [Abstract][Full Text] [Related]
8. Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: Novel strategies to overcome cancer chemoresistance.
Taddia L; D'Arca D; Ferrari S; Marraccini C; Severi L; Ponterini G; Assaraf YG; Marverti G; Costi MP
Drug Resist Updat; 2015 Nov; 23():20-54. PubMed ID: 26690339
[TBL] [Abstract][Full Text] [Related]
9. Nanocarriers in Improving Chemotherapy of Multidrug Resistant Tumors: Key Developments and Perspectives.
Chistiakov DA; Myasoedova VA; Orekhov AN; Bobryshev YV
Curr Pharm Des; 2017; 23(22):3301-3308. PubMed ID: 28403792
[TBL] [Abstract][Full Text] [Related]
10. Chemoresistance and chemosensitization in cholangiocarcinoma.
Marin JJG; Lozano E; Herraez E; Asensio M; Di Giacomo S; Romero MR; Briz O; Serrano MA; Efferth T; Macias RIR
Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1444-1453. PubMed ID: 28600147
[TBL] [Abstract][Full Text] [Related]
11. Impact of alternative splicing on mechanisms of resistance to anticancer drugs.
Reviejo M; Soto M; Lozano E; Asensio M; Martínez-Augustin O; Sánchez de Medina F; Marin JJG
Biochem Pharmacol; 2021 Nov; 193():114810. PubMed ID: 34673012
[TBL] [Abstract][Full Text] [Related]
12. Microenvironment acidity as a major determinant of tumor chemoresistance: Proton pump inhibitors (PPIs) as a novel therapeutic approach.
Taylor S; Spugnini EP; Assaraf YG; Azzarito T; Rauch C; Fais S
Drug Resist Updat; 2015 Nov; 23():69-78. PubMed ID: 26341193
[TBL] [Abstract][Full Text] [Related]
13. Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors.
Dallavalle S; Dobričić V; Lazzarato L; Gazzano E; Machuqueiro M; Pajeva I; Tsakovska I; Zidar N; Fruttero R
Drug Resist Updat; 2020 May; 50():100682. PubMed ID: 32087558
[TBL] [Abstract][Full Text] [Related]
14. New tools for old drugs: Functional genetic screens to optimize current chemotherapy.
Gerhards NM; Rottenberg S
Drug Resist Updat; 2018 Jan; 36():30-46. PubMed ID: 29499836
[TBL] [Abstract][Full Text] [Related]
15. Strategies for overcoming chemotherapy resistance in enterohepatic tumours.
Marin JJ; Castaño B; Blazquez AG; Rosales R; Efferth T; Monte MJ
Curr Mol Med; 2010 Jul; 10(5):467-85. PubMed ID: 20540704
[TBL] [Abstract][Full Text] [Related]
16. Role of transportome in the pharmacogenomics of hepatocellular carcinoma and hepatobiliary cancer.
Alonso-Peña M; Espinosa-Escudero RA; Soto-Muñiz M; Sanchon-Sanchez P; Sanchez-Martin A; Marin JJ
Pharmacogenomics; 2019 Aug; 20(13):957-970. PubMed ID: 31486734
[TBL] [Abstract][Full Text] [Related]
17. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment.
Pérez-Tomás R
Curr Med Chem; 2006; 13(16):1859-76. PubMed ID: 16842198
[TBL] [Abstract][Full Text] [Related]
18. Cancer Cell Resistance Against the Clinically Investigated Thiosemicarbazone COTI-2 Is Based on Formation of Intracellular Copper Complex Glutathione Adducts and ABCC1-Mediated Efflux.
Bormio Nunes JH; Hager S; Mathuber M; Pósa V; Roller A; Enyedy ÉA; Stefanelli A; Berger W; Keppler BK; Heffeter P; Kowol CR
J Med Chem; 2020 Nov; 63(22):13719-13732. PubMed ID: 33190481
[TBL] [Abstract][Full Text] [Related]
19. Role of drug transport and metabolism in the chemoresistance of acute myeloid leukemia.
Marin JJ; Briz O; Rodríguez-Macias G; Díez-Martín JL; Macias RI
Blood Rev; 2016 Jan; 30(1):55-64. PubMed ID: 26321049
[TBL] [Abstract][Full Text] [Related]
20. TAK-ing aim at chemoresistance: The emerging role of MAP3K7 as a target for cancer therapy.
Santoro R; Carbone C; Piro G; Chiao PJ; Melisi D
Drug Resist Updat; 2017 Nov; 33-35():36-42. PubMed ID: 29145973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
